The Ppp2r1b Knockout 3T3-L1 Cell Line is a CRISPR/Cas9-engineered mouse cell model in which the Ppp2r1b gene has been disrupted to eliminate functional PPP2R1B expression. This stable knockout was generated in 3T3-L1 cells, a murine preadipocyte fibroblast line extensively used for mechanistic studies of adipocyte biology. The model provides a defined in vitro system for examining the consequences of altered PP2A scaffold composition in a cellular background that is highly responsive to adipogenic and metabolic cues.
3T3-L1 cells are derived from mouse embryo fibroblast-like precursors and are well established as a model of hormone-induced adipogenic differentiation. Upon appropriate induction, they undergo coordinated transcriptional and metabolic remodeling associated with lipid droplet accumulation, insulin-responsive glucose handling, and lipogenic gene expression. Because of this phenotype, 3T3-L1 cells are widely used to study adipogenesis, insulin signaling, lipid storage, nutrient sensing, and metabolic regulation relevant to obesity, insulin resistance, type 2 diabetes, metabolic syndrome, and related disorders.
PPP2R1B encodes the PP2A scaffold A?? subunit, a structural component that forms complexes with catalytic subunits PPP2CA and PPP2CB together with multiple regulatory B subunit families, including B55, B56, PR72/PR130, and STRN family striatins. Through these holoenzymes, PPP2R1B helps direct serine/threonine dephosphorylation of signaling proteins functioning downstream of insulin, IGF1, PDGF, EGF, serum growth factors, nutrient status, and ceramide-sensitive phosphatase regulation. Altered assembly of PP2A complexes can affect phosphorylation states of AKT, ERK1/2, GSK3??, FOXO1, RB1, and mTORC1 pathway outputs such as RPS6KB1, with downstream consequences for CEBPA, PPARG, and broader lipogenic transcriptional programs. PPP2R1B function is also linked to PP2A regulators including TIPRL and PTPA, placing it within a broader network controlling phosphatase biogenesis and signaling selectivity.
In the 3T3-L1 context, loss of Ppp2r1b offers a relevant model for defining how PP2A complex organization influences adipocyte differentiation and insulin-responsive signaling. This system can be used to examine pathway dependencies between PP2A scaffold usage and PI3K-AKT, MAPK/ERK, and mTOR signaling during preadipocyte proliferation, differentiation, and metabolic maturation. It is also suitable for investigating disease-relevant mechanisms connecting phosphatase dysregulation to impaired adipogenesis, altered lipid accumulation, insulin resistance phenotypes, and growth control.
Applications include insulin stimulation studies followed by western blot analysis of phospho-AKT and phospho-ERK, adipogenic differentiation assays with Oil Red O staining and triglyceride quantification, RT-qPCR or RNA-seq analysis of PPARG-, CEBPA-, and lipogenic gene expression, and glucose uptake assays to assess insulin responsiveness. Researchers may also use co-immunoprecipitation to evaluate PP2A holoenzyme composition, phosphatase activity assays to examine okadaic acid-sensitive signaling, immunofluorescence for subcellular phenotyping, and cell proliferation assays to study RB1-associated cell-cycle regulation. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.
Case Study
